enGene Holdings downgraded by UBS with a new price target
$ENGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UBS downgraded enGene Holdings from Buy to Neutral and set a new price target of $7.00 from $34.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2025 | $26.00 | Overweight | Piper Sandler |
| 2/14/2025 | $34.00 → $7.00 | Buy → Neutral | UBS |
| 12/23/2024 | $25.00 | Buy | H.C. Wainwright |
| 11/27/2024 | $23.00 | Outperform | Raymond James |
| 11/18/2024 | $18.00 | Mkt Outperform | JMP Securities |
| 8/28/2024 | $30.00 | Outperform | Oppenheimer |
| 4/22/2024 | $30.00 | Overweight | Wells Fargo |
| 4/15/2024 | $34.00 | Buy | Guggenheim |
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
Piper Sandler initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $26.00
UBS downgraded enGene Holdings from Buy to Neutral and set a new price target of $7.00 from $34.00 previously
H.C. Wainwright initiated coverage of enGene Holdings with a rating of Buy and set a new price target of $25.00
4 - enGene Holdings Inc. (0001980845) (Issuer)
3 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Hussein Sweiti, M.D., MSc, Chief Medical Officer, with a grant date of September 30, 2025. The inducement award for Dr. Sweiti consists of a non-qualified stock option to purchase an aggregate 600,000 of the Company's common shares. The inducement awards for the other three newly-hired employees consist of non-qualified stock options to purchase an aggregate 57,950 of the Company's common shares. The options each have an exercise price of $6.83 per share, which is equal to the clos
Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regula
Achieved target enrollment milestone for LEGEND trial pivotal cohort in high-risk BCG unresponsive NMIBC with carcinoma in situ LEGEND's pivotal cohort data update planned for 4Q 2025 Detalimogene granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA Biologic License Application (BLA) submission planned for 2H 2026 Cash and marketable securities of $224.9 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update. "Reaching target enrollment in LEGEND'
8-K - enGene Holdings Inc. (0001980845) (Filer)
S-8 - enGene Holdings Inc. (0001980845) (Filer)
10-Q - enGene Holdings Inc. (0001980845) (Filer)
Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regula
Philip Astley-Sparke, William Grossman and Michael Heffernan join the Board Management promotions strengthen clinical and regulatory operations Matthew Boyd named Chief Regulatory Officer, Jill Buck Chief Development Officer, and Katherine Chan Executive Director, Urology Clinical Lead enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical development, and global product launches will support enGene's strategic transit
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal co
Achieved target enrollment milestone for LEGEND trial pivotal cohort in high-risk BCG unresponsive NMIBC with carcinoma in situ LEGEND's pivotal cohort data update planned for 4Q 2025 Detalimogene granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA Biologic License Application (BLA) submission planned for 2H 2026 Cash and marketable securities of $224.9 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update. "Reaching target enrollment in LEGEND'
Additional preliminary data from ongoing LEGEND study of detalimogene in pivotal cohort of BCG-unresponsive NMIBC with CIS anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track EMA Scientific Advice completed; Indicated data could be suitable for a Contingent Marketing Authorization Application Cash and marketable securities of $251.5 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. "We have seen strong
Additional preliminary data from ongoing LEGEND study of detalimogene in BCG-unresponsive NMIBC with CIS, including pivotal cohort, anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track Cash and marketable securities of $272.8 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. "With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our pl
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)